2-oxindole compounds

1. A compound having formula (I):

or a pharmaceutically acceptable salt thereof, wherein

Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R 3 ;

L 1 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,

L 2 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,

Y is CO 2 H or a carboxylic acid bioisostere;

each R 1 and each R 2a is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, OH, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;

R 2b is selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;

or optionally one R 2a and R 2b when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C 1-3 alkyl;

each R 3 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl;

the subscript m is an integer of from 0 to 4; and

the subscript n is an integer of from 0 to 3.

2. The compound of claim 1 , having formula (I′):

or a pharmaceutically acceptable salt thereof, wherein

Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R 3 ;

L 1 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,

L 2 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,

each R 1 and each R 2a is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;

R 2b is selected from the group consisting of H, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;

or optionally one R 2a and R 2b when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C 1-3 alkyl;

each R 3 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl;

the subscript m is an integer of from 0 to 4; and

the subscript n is an integer of from 0 to 3.

3. A compound of claim 1 , wherein Y is selected from the group consisting of:

tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with R, wherein p is 0, 1 or 2 and wherein each R group is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, or C 1 -C 4 alkyl-O—C 1 -C 4 alkyl.

4. A compound of claim 1 , wherein Y is selected from the group consisting of: tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —C 1-6 alkoxy or C 1-4 alkyl-O—C 1-4 alkyl.

5. A compound of claim 1 having the formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

6. A compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof, wherein L 2 is C 1-3 alkylene and wherein said compound is substantially free of other isomers.

7. A compound of claim 1 , wherein Ar is selected from benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

8. A compound of claim 1 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

9. A compound of claim 1 , wherein L 2 is selected from the group consisting of a bond, —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 —, and —CH 2 CH 2 CH 2 —.

10. A compound of claim 1 , wherein n is 1 or 2.

11. A compound of claim 1 , wherein m is 1, 2 or 3.

12. A compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

13. A compound of claim 12 , wherein Ar is selected from benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

14. A compound of claim 12 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

15. A compound of claim 12 , wherein L 2 is selected from the group consisting of a bond, —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 —, and —CH 2 CH 2 CH 2 —.

16. A compound of claim 12 , having a formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

17. A compound of claim 16 , wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

18. A compound of claim 16 , wherein Ar is selected from the group consisting of 1,3-phenylene and 1,4-phenylene, each of which is optionally substituted with from one to two R 3 .

19. A compound of claim 16 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

20. A compound of claim 16 , wherein L 2 is selected from the group consisting

of —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 — and —CH 2 CH 2 CH 2 —.

21. A compound of claim 16 , wherein R 1 is selected from the group consisting of halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, C 3-5 cycloalkyl, and C 2-3 alkenyl.

22. A compound of claim 16 , wherein R 1 is selected from the group consisting of chloro, methyl, cyano, ethyl, cyclopropyl, trifluoromethyl and trifluoromethoxy.

23. A compound of claim 16 , having a formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

24. A compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

25. A compound of claim 24 , wherein R 2b is hydrogen.

26. A compound of claim 24 , wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

27. A compound of claim 24 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

28. A compound of claim 24 , wherein L 2 is selected from the group consisting of a bond, —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 — and —CH 2 CH 2 CH 2 —.

29. A compound of claim 24 , having a formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

30. A compound of claim 29 , wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R 3 .

31. A compound of claim 29 , wherein Ar is selected from the group consisting of 1,3-phenylene and 1,4-phenylene, each of which is optionally substituted with from one to two R 3 .

32. A compound of claim 29 , wherein R 3 is selected from the group consisting of CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 and CH 2 OH.

33. A compound claim 29 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.

34. A compound of claim 29 , wherein L 2 is selected from the group consisting

of —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 — and —CH 2 CH 2 CH 2 —.

35. A compound of claim 29 , wherein R 1 is selected from the group consisting of halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, C 3-5 cycloalkyl, and C 2-3 alkenyl.

36. A compound of claim 29 , wherein R 1 is selected from the group consisting of chloro, methyl, cyano, ethyl, cyclopropyl, trifluoromethyl and trifluoromethoxy.

37. A compound of claim 29 , having a formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

38. A compound of claim 1 or a pharmaceutically acceptable salt thereof, having the formula

39. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.

40. A compound of claim 1 or a pharmaceutically acceptable salt thereof, having the formula

41. A compound of claim 1 or a pharmaceutically acceptable salt thereof, having the formula

42. A compound of claim 1 or a pharmaceutically acceptable salt thereof, having the formula

43. A compound of claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of